XING is looking to fast-track the development and regulatory approval of the diagnostic kit to meet customer needs in the U.S., Europe and the pan-Asian region. These customers have been looking for a fast and accurate point-of-care antigen test as a superior alternate to existing serology tests which measure immune response. The test being developed by XING and its partners is focused on detecting the live virus itself, a reliable indicator of infectivity.
Luina Bio will be developing and implementing the manufacturing of key protein reagents in yeast. These proteins are central to the XING COVID-19 diagnostic test.
“It is estimated time to GMP production using the Luina FMP systems will only take 24 weeks from project commencement to completion,” said Les Tillack, chief executive officer, Luina Bio. “Flexibility is key to being able to respond to important rapid development programs like this.”
Luina Bio and XING are both based in Queensland, Australia, where these reagent product’s will be entirely developed and manufactured.
Luina Bio is one of Australia’s most experienced biopharmaceutical contract manufacturing organizations, offering an inclusive set of services including cGMP manufacture in TGA/APVMA-licensed facilities of recombinant proteins, vaccines, and synthetic molecules for human and veterinary uses. Luina Bio’s Flexible Bio-manufacturing Platform, Luina FMP was developed from over three decades of contract manufacturing experience, knowledge and expertise.